NEW
FIND THE RIGHT FIT. FAST.^*

51% of patients respond to treatment with 84% survival rate at 1 year for responders with EBVALLO, the first and only on-demand T-cell immunotherapy approved for the treatment of relapsed or refractory EBV+ PTLD in Europe^1,2

EBVALLO^® is indicated as monotherapy for the treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory EBV+ PTLD who have received at least one prior therapy. For SOT patients, prior therapy includes chemotherapy unless chemotherapy is considered inappropriate³

EBV+, Epstein-Barr virus positive; PTLD, post-transplant lymphoproliferative disease; ORR, objective response rate; SOT, solid organ transplantation.

*Data on file - Clinical overview EBV+, Epstein-Barr virus positive; ORR, objective response rate; PTLD, post-transplant lymphoproliferative disease; SOT, solid organ transplantation.

EBVALLO is the first and only on-demand allogeneic T-cell immunotherapy approved for the treatment of relapsed or refractory EBV+ PTLD³

EBVALLO demonstrates clinically meaningful outcomes in patients with relapsed or refractory EBV+ PTLD with limited treatment options and poor survival^1,2,6,7,9

Median OS post rituximab +/- chemotherapy failure

0.7 months post HCT⁶
4.1 months post SOT⁷

About EBV+ PTLD

Is the first and only on-demand allogeneic T-cell immunotherapy approved for the treatment of relapsed or refractory EBV+ PTLD³rituximab
+/- chemotherapy failure

About EBVALLO

51% ORR¹
84% 1-yr OS in responders²
In the ALLELE Study

Efficacy

Well tolerated and no reports of immune-related reactions^2,9

Safety

EBV+, Epstein-Barr virus positive; PTLD, post-transplant lymphoproliferative disease; OS, overall survival; HCT, haematopoietic cell transplantation; SOT, solid organ transplantation; ORR, objective response rate

References

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

1. EBVALLO EPAR.
2. Mahadeo KM, et al. Poster 4658. Presented at ASH Annual Meeting and Exposition; Dec. 10–13, 2022; New Orleans, Louisiana, USA. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE).
3. EBVALLO Summary of Product Characteristics. December 2022.
4. Dierickx D, et al. Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med. 2018;378:549–562.
5. Nijland ML, et al. Epstein-Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical
manifestations, diagnosis, and management. Transplant Direct. 2016;2(1):e48.
6. Sanz J, et al. Abstract 1454. Presented at: ASH Annual Meeting and Exposition; December 11–14, 2021; Atlanta. Clinical Outcomes of Patients with Epstein–Barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Hematopoietic Stem Cell Transplantation Who Fail Rituximab:A Multinational, Retrospective Chart Review Study. Blood. 2021;138(Suppl 1):1454.
7. Dharnidharka V, et al. Abstract 2528. Presented at: ASH Annual Meeting and Exposition; December 11–14, 2021; Atlanta. Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study. Blood. 2021;138(Suppl 1):2528.
8. NCT03394365. Available at: https://clinicaltrials.gov/ct2/show/NCT03394365.
9. Mahadeo KM, et al. Abstract 4658. Presented at ASH Annual Meeting and Exposition; Dec. 10–13, 2022; New Orleans, Louisiana, USA. New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein–Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood. 2022;140(Suppl 1):10374–10376.
10. Choquet S, et al. Abstract 258. Presented at ICML; June 18–22, 2021; Virtual Congress. Epstein-Barr virus-driven diseases: a multinational, multicohort, open-label phase 2 study to assess the efficacy and safety of tabelecleucel using an adaptive study design.

This is an international website for EBVALLO®. IMPORTANT: the information on this website is based on the European Summary of Product Characteristics. Prescribing Information and indication may vary per country. You must refer to your country prescribing information. Please be aware we do not take responsibility for accessing such information which may not comply with the regulation or usage in your country.

NEW FIND THE RIGHT FIT. FAST.*

EBVALLO is the first and only on-demand allogeneic T-cell immunotherapy approved for the treatment of relapsed or refractory EBV+ PTLD3​

NEW
FIND THE RIGHT FIT. FAST.^*

EBVALLO is the first and only on-demand allogeneic T-cell immunotherapy approved for the treatment of relapsed or refractory EBV+ PTLD³